Might the risk of the miniscule be sizeable? The UK Nanotechnologies Strategy, published in March 2010, 1 would appear to work under his assumption. Of the three areas covered by the Strategy, two dwell on risk; one addressing potential health, safety and environmental impacts and the other on foreclosing this risk through the regulation of nanomaterials and products into which these are incorporated. In spite of mentioning opportunities in its sub-title, only one section of the Strategy is given over to innovation, and that focuses primarily on the commercialisation of nanotechnologies rather than the science base for technological development as such.
11 Van Calster, Geert (2006) Regulating Nanotechnology in the European Union, European Environmental Law Review, [238] [239] [240] [241] [242] [243] [244] [245] [246] [247] For some sense of scale, a previously used example is that a strand of human hair is approximately 80,000 nanometres in diameter (see Stokes, E. (2009) "Regulating nanotechnologies: sizing up the options", Legal Studies, 29(2), p 281 -304) 13 Frater, L., Stokes, E., Lee, R. and Oriola, T., (2006) Science and Technology Law Review, 8,1-36; Reynolds, G.H. (2003) Nanotechnology and regulatory policy: three futures, Harvard Journal of Law and Technology, 17, 179 -209; Segal, S. (2004) Environmental regulation of nanotechnology: avoiding big mistakes for small machines, Nanotechnology Law & Business, 1, 290 -303; and Wilson, R.F. (2006) Nanotechnology: the challenge of regulating known unknowns, Journal of Law, Medicine and Ethics, 34, [704] [705] [706] [707] [708] [709] [710] [711] [712] [713] Royal Society and Royal Academy of Engineering (RS/RAEng) (2004) Nanoscience and nanotechnologies: opportunities and uncertainties, London, Royal Society.
ESRC BRASS Research Centre, Cardiff University single regulatory framework at the level of the European Community and thus there will need to be an adaption of existing provisions from a plethora of laws to address nanosubstances 22 .
There is some awareness of this issue within the E.U. The regulatory gap analysis by Frater et al (referenced above) concluded that while gaps did exist in the ability of the then existing regulatory framework to regulate nanosubstances, such gaps were not insurmountable 27 . The question then becomes one of how well does the mapping of existing regulation onto nanosubstances match the specific contours of the substances being regulated? It is this question, in the context solely of REACH, to which we now turn.
REACH -An Overview
At its most basic, REACH requires the generation of data on the intrinsic properties of certain chemical substances (likely to be somewhere between 30,000 and 45,000 of the more than 105,000 substances currently on the market 28 ). In what has been described as a form of hybrid governance 29 , data gathering falls upon the private sector in the form of manufacturers, importers and, in limited circumstances, downstream users of those substances and should be followed by the registration of such substances, together with the testing data, with a newly created EU regulatory th Report) which called for a process of adaptive management of current regulatory structures. 28 This estimate is vague as the European Chemicals Agency has not performed any evaluation of the 145,000 substances pre-registered with them in 2008 as potentially falling within the remit of the Regulation (http://apps.echa.europa.eu/preregistered/pre-registered-sub.aspx#whatisthislistheader). It is likely that not all 145,000 substances which were pre -registered will go on to be registered and only time will tell the actual numb er of substances captured by REACH. 29 Hey, C., Klaus, J. and Axel, V. (2007) forms of substances in Annexes V and IV, there are inherent, implicit (and inaccurate) assumptions in the Regulation that the risk of a substance is the same at whatever scale. Such an assumption could mean that an existing risk assessment of a substance at the conventional scale would be sufficient for REACH exemption or exclusion of the substance at the nanoscale. The second is that companies which currently manufacture or import the nano forms of substances in Annexes V and IV, and who may have thought they were exempt from certain of the provisions of REACH, may find themselves subject to obligations in the future if our scientific understanding of the intrinsic properties of nanosubstances increases and the above assumptions are displaced.
The Registration Obligation
The registration obligation under Article 6 of REACH is volume-based with a one tonne de minimis threshold. As a starting point, it thus appears that a manufacturer or importer of any nanosubstance in quantities greater than one tonne per year will be captured under the REACH registration provisions. Although production volumes of nanoscale substances may be currently low, certain companies have do the capacity to annually produce metric tonnes of silver, copper and aluminium nanoparticles, among has been described as the 'cornerstone' of the regulation. 59 However, the CA Document muddies the waters somewhat with the following commentary:
"The tonnage triggers for registration apply to the total volume of a substance manufactured or imported by a registrant. Thus, for substances which exist both in bulk form and in a nanoform, the total volume determines the need and timing for registration and the information requirements" 60 .
From this, it would seem that if a manufacturer of carbon (who produces, for the sake of example, more than 1000 tonnes of carbon per year) also produces an amount of carbon nanotubes ("CNTs"), these CNTs would be registered along with the (bulk form) carbon whatever their volume of manufacture. However, what the Commission fails to note in this part of the CA Document (and which is discussed in greater detail below) is that this 'bulk substance + nano substance' combination of volume for registration purposes should only apply where the substances, in their different forms, are considered the "same". If they are not, such addition would be a wholly inaccurate approach.
Under Annex VI of REACH, the registration dossier for a substance must include information on the manufacturing process(es) and "all identified uses". In the context of risk assessment (discussed in more detail below), registration under REACH calls, highlighted in this paper, for a review of REACH to specifically address concerns from nanosubstances, it is perfectly plausible that the requirement of a CSR for all nanosubstance registrations might then be introduced.
Phase-In or Non-Phase-In, That is the Question (of Equivalence)
The following sections discuss, in the context of REACH, the broad question of whether substances at the nanoscale can be considered equivalent, under the Regulation, to the ir bulk counterparts and, if not, in which specific contexts and to what degree. We begin by looking at the distinctions made in REACH between certain classes of substance for the purpose of regulatory compliance deadlines.
The chemicals regime in the EU prior to REACH 69 split substances into "new" substances (essentially, those put on the market after 1981) and "existing" substances (those already on the market prior to 1981). While REACH does not copy this approach, there is still a divide between "phase-in" and "non-phase-in substances"
when it comes to certain matters, such as deadlines for registration. A phase-in substance is one which meets the criteria set out in Article 3 (20) number when pre-registration presupposes the existence of such a number, thereby qualifying the substance for phase-in status) is not clear.
Sameness and Substance Identification in SIEF Formation
The important question discussed above of equivalence goes beyond the issue of phase-in or non-phase-in status. Let us say, for example, that a manufacturer of carbon nanotubes in quantities greater than one tonner per year has decided (on whatever basis) that their products meet the criteria for "phase-in" substances and has pre-registered them accordingly using the EINECS number for carbon. At some point post 1 January 2009, (s)he will then be allocated to what is known as a SIEF, a substance information exchange forum. Participation in the SIEF is mandatory (with limited exceptions) for all potential registrants, downstream users and third parties who have submitted information to ECHA on "…the same phase-in substance"
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(own emphasis added). In basic terms, the SIEF pulls together everyone who has informed ECHA that they intend to register the "same substance" and then obliges them to share existing vertebrate animal test data and to agree on the generation of new test data for the substance. 84 Going forward, one entity from the SIEF then assumes the role of "Lead Registrant" and submits the registration dossier for the substance on behalf of all of the SIEF members (the 'one substance, one registration' principle) 85 . In our example, the CNT manufacturer will be nominally allocated to the carbon SIEF. The question then is whether this is or is not appropriate. There is, to put it simply, a lack of any appropriate framework in which assessment might occur. At the same time, this is not a static field and SCENIHR comment that there has been improvement in the means to assess the risks from nanosubstances since its reports in 2007. One of the issues goes the lack of appropriate standardised testing protocols. As Geert Dancet puts it: "to decide for legislative purposes whether a nanoscale particle is dangerous to human health requires not only adequate and internationally recognised test methods, but also internationally agreed criteria on which test results can be used to classify a substance as such".
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On a practical level, it appears therefore that, at the moment, current testing approaches will be required to bridge the methodological gap in the assessment of nanosubstances. The European Commission comments that, "Until specific test guidelines for nanomaterials exist, testing will have to be carried out according to risks of nanomaterials. See: http://ec.europa.eu/health/ph_risk/committees/04_scenihr/docs/scenihr_o_010.pdf, SCENIHR (2007b), Opinion on the scientific aspects of the existing and proposed definitions relating to products of nanoscience and nanotechnology. See: ttp://ec.europa.eu/health/ph_risk/committees/04_scenihr/docs/scenihr_o_012.pdf 97 SCENIHR, n. 67, p9 98 European NanOSH Conference -Nanotechnologies: A Critical Area in Occupational Safety and Health, 3-5 December 2007, Marina Congress Center, Helsinki, Finland. This is essentially the same conclusion as that of the Dutch National Institute for Public Health and the Environment. In 2009, they attempted a "mock" registration of nanosilver to see how, in practice, REACH applied to nanosubstances. One of their main conclusions was that ".. approaches as best as possible to his nanosubstance (whic h runs the risk that the registration dossier will fail evaluation by EHCA, a matter to which we now turn)?
ECHA Evaluation
The evaluation process under REACH is a means by which ECHA can call on those who have submitted registration dossiers to provide additional or better information on the substances registered 102 . This is in two parts: (a) dossier evaluation; and (b) substance evaluation. Whereas dossier evaluation can, in many respects, be thought of as an administrative box-checking exercise, substance evaluation operates in much greater depth. As a first task in the substance evaluation process, ECHA (in coordination with the Member States), has to develop criteria for prioritising substances, on a "risk based" approach, with a view to further evaluation 103 . These criteria (based on hazard information, exposure information and substance tonnage) will lead into a This does, however, raise an interesting query. In the CA Document, it is made clear that if a nanosubstance is put forward by a Member State as being a SVHC which should be included in Annex XIV, the dossier which details the reasoning behind the Member State's proposal should clarify that it is the nanoform of the subject which is thought to meet the SVHC criteria (and not the bulk form). This seems clear enough.
However, there is no corresponding advice for when dossiers are prepared for substances thought to meet the SVHC criteria in their bulk form only. For example, anthracene, used for the artificial production of the red dye alizarin as well as in certain wood preservatives, appears on the candidate list. Nowhere in the linked SVHC Support Document 119 is there reference to which form of anthracene is thought to be a SVHC. We might assume that this refers to the conventional form, but does this then mean that the nano form of a bulk substance identified as a SVHC is also considered a SVHC? If not, should this not be made explicit?
Article 60 of REACH sets out the necessary conditions for the authorisation (i.e.
continued market presence) of a SVHC to be granted -either: (i) the risk from the substance subject to authorisation must be "adequately controlled"; or (ii) the socioeconomic benefits from the substance must outweigh the risks and there must be no Guidance by ECHA on how to assess socioeconomic benefits has yet to be published. Given the dichotomy between the potential for nanosubstances to bring improvements to a variety of aspects of our lives and the environment and the potential for such nanosubstances to be intrinsically harmful, it is 120 Section 6.4 of Annex I of REACH details that for any exposure scenario, the risk to humans and the environment can be considered to be adequately controlled, throughout the lifecycle of the substance that results from manufacture or identified uses, if: (a) the exposure levels estimated in Section 6.2 do not exceed the appropriate DNEL or the PNEC, as determined in Sections 1 and 3, respectively, and (b) likely there will be some very interesting arguments when it comes to the socioeconomic analysis of any given nanosubstance labelled a SVHC which seeks authorisation. There are also some very interesting issues here when it comes to the question of "suitable alternatives". As noted above, if there are "suitable alternatives"
for a SVHC which is on the Annex XIV list which cannot take advantage of the 'adequate control authorisation' in Article 60(2), those alternatives must be used. As ECHA put it, "If the analysis of alternatives reveals that there is a suitable alternative, the applicant must submit a substitution plan, explaining how he intends to replace the substance by the alternative" 122 . Article 60(5) of REACH details that when assessing whether suitable alternative substances or technologies are available, all relevant aspects shall be taken into account by the Commission, including: (a) whether the transfer to alternatives would result in reduced overall risks to human health and the environment (taking into account the appropriateness and effectiveness of risk management measures); and (b) the technical and economic feasibility of alternatives for the applicant. This issue of "suitable alternatives" would seem to cut both ways when it comes to nanosubstances. For bulk SVHCs which are on the Annex XIV list, it may be that a suitable alternative substance is not another bulk substance, but instead a nanosubstance. If this is so, REACH may drive the development of nanosubstances as replacements for bulk SVHCs (although there would appear to be two instantly apparent problems which go to economic and technical suitability:
namely, the cost of nanosubstance production and extant availability of an alternative). At the same time, for nanosubstances which are SVHCs on the Annex XIV list, how will a "suitable alternative" be assessed? There is, as yet, no guidance the likelihood and severity of an event occurring due to the physicochemical properties of the substance as determined in Section 2 is negligible. 121 Article 60(4), REACH on this. S ay, for example, a particular nanosubstance is produced and used on products, making them ten times lighter than they would be were conventional substances used. Say also that this particular nanosubstance is a SVHC on Annex XIV. In this situation, the obvious "suitable alternative" is the conventional substance, although this ignores the entire reasoning behind the production of the nanosubstance in the first place. Where there is a "suitable alternative", the drafting of Article 60 (4) of REACH prevents a socio-economic analysis of the SVHC. Suitability of the alternative is determined on the basis of the risk reduction of the alternative and its economic and technical feasibility. There is here no potential (as REACH is drafted)
for any social benefits to be considered. As outlined above, this may have significant impacts when it comes to granting authorisations for nanosubstances.
Concluding Thoughts
Much of the preceding discussion on the application of REACH is on the potential, practical application of REACH and how it could, logically, map onto the broad field of nanosubstances. As van Calster puts it, "…it is clear that, while the cornerstone of the EU's chemical legislation certainly in theory could be applied to nanotechnological applications, its application in practice is not geared towards nanotechnology" 123 . Given this, the REACH-nano debate is somewhat normative and, as a corollary, legal scholars working in the field tend to couch their opinions in suitably qualified language 124 . Nothing in this area is set in stone. As a bare 122 http://guidance.echa.europa.eu/authorisation_en.htm 123 Van Calster, n.6. p.242 124 See, for example, Desmoulin (n.27, p347): "… REACH should be an appropriate legal instrument for obtaining information on the potential toxic and ecotoxic effects of nanosubstances" (own emphasis added). The Royal Commission on Environmental Pollution (n.22, p62) comment that, "At least in minimum, REACH should apply to nanosubstances and should generate an amount of information on their intrinsic properties while, at the same time, banning or restricting the use of nanosubstances of very high concern (irrespective of whether they have been through the registration process or not). As Bryden concludes, "…REACH will be the primary regulatory tool for gathering information on new nano-materials" 125 .
At the same time, REACH should not hit the same regulatory brick wall as other regimes (which are, in part, robbed of their regulatory potential by a lack of commonly agreed data on the intrinsic properties of substances 126 ); instead, it should drive the testing of nanosubstances and produce new testing methodologies acting, to some degree, as a stimulus for the regulation of nanosubstances in other areas (such as worker health or product safety).
The Commission has promised to carefully monitor the implementation of REACH in the context of nanosubstances, in light of which "…current provisions, including quantitative triggers and information requirements, may have to be modified" 127 . The UK Strategy has stated that it will attempt, as an action point, to "influence changes made to … REACH in order to ensure (nanomaterials) are robustly covered." 128 In the Strategy, the Government expresses concern that the design of REACH without reference to nanomaterials may produce implementation issues. Commission, n.38, p5 . It is also worth noting here that the Commission is scheduled to update its Communication on the "Regulatory Aspects of Nanomaterials" in 2011. It may well be that, in light of the practical application of REACH by that date, amendments are proposed to the Regulation to account for nanosubstance related issues. In addition, three projects to potentially amend and update REACH guidance to address specific nanosubstance issues were launched in January 2010 by the European Commission's Directorate General for Environment (on which, see: http://ec.europa.eu/dgs/jrc/index.cfm?id=1410&obj_id=9830&dt_code=NWS&lang=en ). 128 The Strategy at p.5.
